MEDA seeks marketing authorization for Zyclara in Europe

Download PDF Copy

Jun 23 2011

“Zyclara will strengthen Meda's dermatology franchise in Europe. We look forward to provide AK patients with a new product that can treat larger areas of the skin”

MEDA: The marketing authorization application for the patented product Zyclara (imiquimod 3.75% cream) has been filed with the European Medicines Agency (EMA). Zyclara has been documented for once-daily topical treatment of actinic keratosis (AK).

Zyclara expands the treatment area to the full face or balding scalp and could become a first line therapy for AK. More than 1,400 patients have been included in seven clinical studies.

"Zyclara will strengthen Meda's dermatology franchise in Europe. We look forward to provide AK patients with a new product that can treat larger areas of the skin", says Anders Lönner, CEO of Meda.

Source:

MEDA AB

Posted in: Medical Condition News | Pharmaceutical News

Comments (0)

Download PDF Copy

Suggested Reading

Could serotonin supplements become the next hair loss treatment?

Genetic variants influencing vitamin D synthesis, metabolism, and transport

Can saliva and tears replace blood tests for vitamin D and glucose?

How breast milk changes from day to night and why timing matters

Fad diets and supplements fuel new wave of hidden skin problems, study finds

Can oral bacteria make heart disease worse?

AI-powered sweat sensor predicts anxiety before symptoms appear

Common vegetable oils speed up skin regeneration

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

(Logout)

Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.